Analyst Price Target is $4.00
▲ +119.78% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Ampio Pharmaceuticals in the last 3 months. The average price target is $4.00, with a high forecast of $4.00 and a low forecast of $4.00. The average price target represents a 119.78% upside from the last price of $1.82.
Current Consensus is
The current consensus among 1 polled investment analysts is to buy stock in Ampio Pharmaceuticals.
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunology-based therapies for the treatment of prevalent inflammatory conditions in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-016, an intravenous treatment that is in Phase I/II clinical trial for COVID-19 patients with respiratory illness; and AP-014, an inhaled treatment that is in Phase I clinical trial for COVID-19 induced respiratory distress. The company is headquartered in Englewood, Colorado.